化合物 BPR1J-097|T2272|TargetMol

BPR1J-097
1327167-19-0

￥2484 25mg 起订

￥3730 50mg 起订

￥786 5mg 起订

上海更新日期：2024-09-30

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 BPR1J-097

英文名称：: BPR1J-097

CAS号：: 1327167-19-0

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.3%

产品类别：: 抑制剂

货号：: T2272

Product Introduction

Bioactivity

名称	BPR1J-097
描述	BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).
激酶实验	Kinase assays: To assay Plk1 and Aurora A kinase activity, cells are lysed after 13 hrs release in the presence of SBE13 after double thymidine block, and kinases are immunoprecipitated from lysates using antibodies as described. In brief, for each immunoprecipitation 800 μg of total protein were incubated with 1.5 μg Plk1 antibody cocktail, 3 μg Plk2 antibody, 3 μg Plk3 antibody, or 5 μg Aurora A antibody, respectively, for 2 hrs at 4°C on a rotator. Immunoprecipitated protein is collected using Protein G Agarose beads. The Plk1, Plk2 and Plk3 immunoprecipitates are incubated with 1 μg casein and with 1 μCi of [γ32-P]ATP for 30 min at 37°C in kinase buffer. The Aurora A immunoprecipitates are incubated with 0.5 μl Histone and with 1 μCi of [γ32-P]ATP for 60 min at room temperature in kinase buffer. Products from the kinase assays are fractionated on 10% Bis-Tris-polyacrylamide gels, and the phosphorylated substrate is visualized by autoradiography after an exposure of 12 to 36 hrs. An equal amount of immunoprecipitates is subjected to western blot analysis to confirm equal loading of Plk1, Plk2, Plk3 or Aurora A protein in kinase reactions. Immunoprecipitated Plk1 after 13 hrs release in the presence of SBE13 is assayed after de-phosphorylation using λ protein phosphatase and compared to kinase activity of endogenous immunoprecipitated Plk1. Activity of Plk1 kinase with and wiiiuithout de-phosphorylation is compared and the ratio between de-phosphorylated and "normal" endogenous immunoprecipitated Plk1 kinase activity is calculated.
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 11 mg/mL (21.29 mM), Sonication is recommended.
关键字	CD135 \| Fms like tyrosine kinase 3 \| BPR-1J-097 \| BPR1J-097 \| FLT3 \| Cluster of differentiation antigen 135 \| inhibit \| BPR1J 097 \| Inhibitor
相关产品	SGI-1776 \| Gilteritinib \| KW-2449 \| Sorafenib tosylate \| Sunitinib Malate \| 4SC-203 \| Tandutinib \| Nintedanib \| Sorafenib \| Pexidartinib \| Fedratinib \| UNC2025
相关库	抑制剂库 \| 血管生成库 \| 抗癌活性化合物库 \| 经典已知活性库 \| 抗癌化合物库 \| 已知活性化合物库 \| 激酶抑制剂库 \| NO PAINS 化合物库 \| 抗肺癌化合物库 \| 酪氨酸激酶分子库

BPR1J097|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务